Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of ABP 959 versus eculizumab in adult paroxysmal nocturnal hemoglobinuria
2017-001418-27Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eculizumab-aeeb in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Amgen. Primary endpoint: Control of intravascular hemolysis at week 27. Started Jul 2017; status: completed.
02
Drugs
eculizumab-aeeb
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-001418-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001418-27.